Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Meyer, Alison E., Catherine E. Gatza, Tam How, Mark Starr, Andrew B. Nixon, and Gerard C. Blobe. “Role of TGF-β receptor III localization in polarity and breast cancer progression..” Molecular Biology of the Cell 25, no. 15 (August 2014): 2291–2304. https://doi.org/10.1091/mbc.E14-03-0825.

PMID
24870032
Full Text

Elderbroom, Jennifer L., Jennifer J. Huang, Catherine E. Gatza, Jian Chen, Tam How, Mark Starr, Andrew B. Nixon, and Gerard C. Blobe. “Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion..” Molecular Biology of the Cell 25, no. 16 (August 2014): 2320–32. https://doi.org/10.1091/mbc.E13-09-0524.

PMID
24966170
Full Text

Dellinger, A. E., A. B. Nixon, and H. Pang. “Integrative pathway analysis using Graph-Based learning with applications to TCGA colon and ovarian data.” Cancer Informatics 13, no. SUPPL.4 (July 28, 2014). https://doi.org/10.4137/CIN.S13634.

Full Text

Kumar, S., C. C. Pan, J. C. Bloodworth, A. B. Nixon, C. Theuer, D. G. Hoyt, and N. Y. Lee. “Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling..” Oncogene 33, no. 30 (July 24, 2014): 3970–79. https://doi.org/10.1038/onc.2013.386.

PMID
24077288
Full Text

Knelson, Erik H., Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, and Gerard C. Blobe. “Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth..” The Journal of Clinical Investigation 124, no. 7 (July 2014): 3016–31. https://doi.org/10.1172/JCI74270.

PMID
24937430
Full Text

Liu, Yingmiao, Mark D. Starr, John C. Brady, Andrew Dellinger, Herbert Pang, Bonne Adams, Charles P. Theuer, Nam Y. Lee, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer..” Cancer Med 3, no. 3 (June 2014): 580–91. https://doi.org/10.1002/cam4.207.

PMID
24574330
Full Text

Gatza, Catherine E., Jennifer L. Elderbroom, Sun Young Oh, Mark D. Starr, Andrew B. Nixon, and Gerard C. Blobe. “The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells..” Neoplasia (New York, N.Y.) 16, no. 6 (June 2014): 489–500. https://doi.org/10.1016/j.neo.2014.05.008.

PMID
25077702
Full Text

Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial..” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.

Full Text

Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206..” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.

Full Text

Hatch, Ace Joseph, Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Chen Jiang, Alexander Sibley, et al. “Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance)..” In Journal of Clinical Oncology, 32:11022–11022. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11022.

Full Text

Pages